Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteasome inhibitors in mantle cell lymphoma.
Holkova B, Grant S. Holkova B, et al. Best Pract Res Clin Haematol. 2012 Jun;25(2):133-41. doi: 10.1016/j.beha.2012.04.007. Epub 2012 May 16. Best Pract Res Clin Haematol. 2012. PMID: 22687449 Free PMC article. Review.
Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bose P, Batalo MS, Holkova B, Grant S. Bose P, et al. Among authors: holkova b. Expert Opin Pharmacother. 2014 Nov;15(16):2443-59. doi: 10.1517/14656566.2014.965142. Epub 2014 Sep 29. Expert Opin Pharmacother. 2014. PMID: 25263936 Free PMC article. Review.
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. Holkova B, et al. Leuk Lymphoma. 2017 Jun;58(6):1349-1357. doi: 10.1080/10428194.2016.1276287. Epub 2017 Jan 19. Leuk Lymphoma. 2017. PMID: 28103725 Free PMC article. Clinical Trial.
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. Yazbeck V, et al. Among authors: holkova b. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30122201 Clinical Trial.
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Holkova B, et al. Leuk Lymphoma. 2021 May;62(5):1187-1194. doi: 10.1080/10428194.2020.1861270. Epub 2020 Dec 28. Leuk Lymphoma. 2021. PMID: 33356689 Free PMC article. Clinical Trial.
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. Holkova B, et al. Leuk Lymphoma. 2016;57(3):635-43. doi: 10.3109/10428194.2015.1075019. Epub 2015 Oct 12. Leuk Lymphoma. 2016. PMID: 26284612 Free PMC article. Clinical Trial.
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. Holkova B, et al. Clin Cancer Res. 2013 Apr 1;19(7):1873-83. doi: 10.1158/1078-0432.CCR-12-2926. Epub 2013 Mar 20. Clin Cancer Res. 2013. PMID: 23515411 Free PMC article. Clinical Trial.
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Holkova B, et al. Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23. Clin Cancer Res. 2014. PMID: 25248382 Free PMC article. Clinical Trial.
27 results